Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunoprecise Antibodies Ltd (NQ: IPA ) 0.9800 +0.0030 (+0.31%) Streaming Delayed Price Updated: 3:56 PM EDT, Jul 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 50,502 Open 0.9600 Bid (Size) 0.9500 (10) Ask (Size) 0.9700 (10) Prev. Close 0.9770 Today's Range 0.9500 - 0.9800 52wk Range 0.8900 - 2.940 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024 July 15, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer June 27, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire Performance YTD -42.35% -42.35% 1 Month -6.22% -6.22% 3 Month -20.97% -20.97% 6 Month -35.53% -35.53% 1 Year -64.36% -64.36% More News Read More IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™ June 25, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire Earnings Outlook For ImmunoPrecise Antibodies March 13, 2024 Via Benzinga ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology June 12, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery June 10, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire EXCLUSIVE: ImmunoPrecise Antibodies' Subsidiary Releases Software With Customizable Interface For AI-Driven Drug Discovery June 10, 2024 Via Benzinga IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR) June 04, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results April 22, 2024 Via ACCESSWIRE ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments April 12, 2024 Via ACCESSWIRE InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications March 28, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire EXCLUSIVE: Immunoprecise Antibodies and InterSystems Integrate Vector Search With LENSai For AI-Driven Healthcare Applications March 28, 2024 Via Benzinga IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments March 20, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire IPA Stock Earnings: ImmunoPrecise Antibodies Misses EPS, Beats Revenue for Q3 2024 March 14, 2024 Via InvestorPlace IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* March 14, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire Earnings Scheduled For March 14, 2024 March 14, 2024 Via Benzinga ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology March 08, 2024 Via ACCESSWIRE Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session March 07, 2024 Via Benzinga IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology March 07, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024 March 04, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire ImmunoPrecise Antibodies (NASDAQ:IPA) Is Changing How We Look At The Complex World Of Antibody Discovery February 13, 2024 Via ACCESSWIRE ImmunoPrecise Antibodies (NASDAQ: IPA) Is Changing How We Look At The Complex World Of Antibody Discovery February 12, 2024 Via Benzinga ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms January 10, 2024 Via ACCESSWIRE ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms January 09, 2024 Via Benzinga IPA Stock Earnings: ImmunoPrecise Antibodies Beats EPS, Beats Revenue for Q2 2024 December 14, 2023 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
